An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
Clinical trial NCT07503028 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07503028
- Sponsor
- Celregen Therapeutics
- Status
- ENROLLING_BY_INVITATION
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-17
- Primary completion
- 2028-01-18
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.